Frequency determines what you are actually running. The same milligram dose at weekly and daily intervals produces completely different pharmacokinetics. They are not the same protocol.
Most researchers evaluate their Retatrutide protocol at week two or three. The problem is that a compound with a 6-day half-life has not reached steady state yet at that point. What is being evaluated is a moving target — not a stable protocol. How often you inject changes what the compound is actually doing in the system far more than most people account for.
This guide covers what frequency actually means in the context of pharmacokinetics, why the same weekly milligram total produces a different research experience depending on how it is split, and what the data shows across three delivery scenarios.
Researchers running Retatrutide who are not getting expected results and are not sure whether the protocol is the problem or the evaluation window is.
Researchers who have changed frequency without understanding what changed mechanistically — and want to know what actually shifted.
Anyone trying to understand why two protocols running the same milligram dose can produce completely different outcomes.
The half-life problem most researchers ignore
Retatrutide has a half-life of approximately six days. That is a long time relative to most research compounds. It means the compound is still present in significant concentration almost a week after a single injection — which is why it accumulates so substantially with repeated dosing.
Half-life refers to how long it takes for the concentration of a compound to drop by half. A six-day half-life does not mean the compound is gone in six days. It means half of whatever was in the system is still present after six days. At day twelve, half of that half remains. The compound stacks on itself with every injection added before the previous dose fully clears.
This is not a flaw. It is a feature of how the compound works. But it means the frequency of injection has an enormous effect on what the actual running concentration looks like at steady state — and most researchers significantly underestimate that effect.
The Protocol Intelligence Tool maps every compound in your stack to its receptor targets and flags where two compounds are driving the same binding site. For this combination it identifies the shared pathways and shows exactly where the signals converge. That picture is what the receptor map requires before any stacking decision can be evaluated accurately.
Run the Protocol Intelligence Tool| Frequency | Per injection | Peak | Trough | Accumulation factor | Days to steady state |
|---|---|---|---|---|---|
| Daily | 0.29 mg | 2.76 mg | 2.41 mg | ~9.19x | ~37 days |
| Every two days | 0.5 mg | Middle range | Middle range | Between daily and weekly | ~19 doses |
| Once weekly | 2 mg | 3.53 mg | 1.65 mg | ~1.77x | ~6 weeks |
What the data shows across three delivery scenarios
All three scenarios below use the same 2 mg weekly total. The only variable is how often that total is delivered.
Daily — 0.29 mg per day
Daily dosing produces the most stable concentration profile. Because the compound accumulates continuously and clears slowly, the system builds to a tight steady-state band — peak at approximately 2.76 mg, trough at approximately 2.41 mg. The gap between the highest and lowest point in a cycle is relatively small. The accumulation factor is approximately 9.19x the single dose, which reflects how the compound stacks under daily delivery. Steady state takes approximately 37 days.
Every two days — 0.5 mg
Every-two-day frequency sits in the middle. Accumulation factor falls between daily and weekly. The peak-to-trough swing is wider than daily but narrower than once-weekly. This frequency reaches steady state in approximately 19 doses — faster than weekly and slower than daily. For researchers who want more concentration stability than once-weekly provides without committing to daily injection, the data suggests this is a reasonable middle position.
Once weekly — 2 mg
Once-weekly dosing produces the widest concentration swing. Peak reaches approximately 3.53 mg — noticeably higher than the daily scenario. But the trough drops to approximately 1.65 mg before the next injection. That is a swing of nearly 1.9 mg within a single weekly cycle. Accumulation factor is only 1.77x because the compound clears substantially between doses. Steady state takes approximately six weeks at this frequency.
Neither approach is wrong. What matters is understanding which one the protocol is actually running — because the experience at peak concentration versus trough can feel meaningfully different, and that difference is frequently misread as tolerance or inconsistency when it is expected pharmacokinetic behavior.
The free protocol check maps your current compounds to the bottleneck they were built to solve. If the bottleneck has already been addressed, it flags it. Before adding a second compound, knowing which variable is actually limiting the result is the more useful starting point than assuming more is better.
Run the Free Protocol CheckWhy steady state is the only valid evaluation window
Steady state is the point where each new dose adds approximately the same amount the previous dose contributed to the remaining concentration. The system is in equilibrium. At steady state the peak and trough become predictable and repeatable — which is when actual protocol evaluation becomes possible.
Before steady state, concentration is still climbing. A researcher who starts a weekly 2 mg protocol and evaluates it at week three is evaluating something that has not stabilized. At six weeks — when steady state is finally established — the experience may be noticeably different from what it was at week three. That difference is not the compound changing. It is the protocol finally reaching the level it was always building toward.
This is one of the most common evaluation errors in Retatrutide research. Protocols get adjusted, stacked, or abandoned before they have ever run at steady state. The data from those early weeks is real, but it is not representative of what the protocol does at full accumulation.
Does injecting retatrutide weekly vs daily change what I am actually running?
Yes. The same weekly milligram total produces completely different peak and trough concentrations depending on how often it is split. Weekly injection creates a higher single-dose peak and a much wider swing before the next injection. Daily injection produces a tighter, more stable accumulation window with significantly less variability between doses.
What is steady state and why does it matter for retatrutide?
Steady state is the point where the amount entering the system each dose roughly equals what the previous dose contributed to the remaining concentration. Because retatrutide has a 6-day half-life, it takes approximately 6 weeks at weekly frequency to reach steady state. Evaluating results before that window closes means evaluating a protocol that is still building — not one that has stabilized.
Why does the 6-day half-life make frequency so important?
A 6-day half-life means retatrutide accumulates significantly between doses. At daily frequency the accumulation factor is approximately 9x the single dose — concentration builds and stabilizes into a narrow band. At weekly frequency the accumulation factor drops to roughly 1.77x, producing a much wider swing between peak and trough. The same milligram amount behaves very differently depending on how it is delivered.
Is every two days a better option than daily or weekly?
Every-two-day frequency sits between daily and weekly on both concentration stability and accumulation factor. It reaches steady state faster than weekly and produces less swing than a once-per-week protocol. Whether it is the right choice depends on what the specific protocol is optimizing for — stable exposure or distinct peaks.
How long should I run retatrutide before drawing any conclusions?
Based on the half-life data, research suggests a minimum of six weeks before evaluating a weekly protocol. Daily dosing reaches steady state in approximately 37 days. Evaluating results before steady state is reached means evaluating a protocol that has not yet stabilized — which makes it impossible to accurately assess what the compound is actually doing.
Full stack visualizer with receptor overlap detection. Deep bottleneck analysis with compound-specific routing. 50+ research deep dives. The complete guide library. One membership.
See What Members GetFor educational and research purposes only | Not medical advice | Not for human use guidance | Project Theo